SCHEMBL8736819

SCHEMBL8736819

c1ccc2cc(-c3c4ccccc4c(-c4ccc5cc(-c6ccc(-n7c8ccccc8c8cnccc87)cc6)ccc5c4)c4ccccc34)ccc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 2/20 0.43
CYP11B2 P19099 2/20 0.43
CYP17A1 P05093 1/20 0.43
CYP19A1 P11511 1/20 0.43
MAOA P21397 4/20 0.40
MAOB P27338 4/20 0.40
ACHE P22303 1/20 0.40
MAPK10 P53779 8/20 0.40
MAPK9 P45984 7/20 0.40
MAPK8 P45983 2/20 0.40
KDM4E B2RXH2 1/20 0.37
ATM Q13315 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PRKCZ Q05513 1/20 0.37
TUBB4A P04350 1/20 0.37
TUBB P07437 1/20 0.37
TUBA3C P0DPH7 1/20 0.37
TUBA1B P68363 1/20 0.37
TUBA4A P68366 1/20 0.37
TUBB4B P68371 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6114410 0.98 CYP11B1 (0.40) CYP11B1CYP11B2CYP17A1CYP19A1MAOA
SCHEMBL1963659 0.96 CYP11B1 (0.41) CYP11B1CYP11B2CYP17A1CYP19A1MAOA
SCHEMBL1964128 0.96 CYP11B1 (0.41) CYP11B1CYP11B2CYP17A1CYP19A1MAOA
SCHEMBL6114261 0.96 CYP11B1 (0.41) CYP11B1CYP11B2CYP17A1CYP19A1MAOA
SCHEMBL6114117 0.94 MAPK10 (0.42) CYP11B1CYP11B2CYP17A1CYP19A1MAOA
SCHEMBL17680043 0.92 CYP17A1 (0.44) CYP11B1CYP11B2CYP17A1CYP19A1MAPK10
SCHEMBL8735627 0.92 CYP17A1 (0.41) CYP11B1CYP11B2CYP17A1CYP19A1MAPK10
SCHEMBL12168978 0.92 CYP17A1 (0.44) CYP11B1CYP11B2CYP17A1CYP19A1MAPK10
SCHEMBL6114362 0.92 CYP17A1 (0.44) CYP11B1CYP11B2CYP17A1CYP19A1MAPK10
SCHEMBL8737122 0.92 CYP17A1 (0.44) CYP11B1CYP11B2CYP17A1CYP19A1MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9755152-B2 Compound having substituted anthracene ring structure and pyridoindole ring structure, and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2017-09-05 US disclosed
US-9755152-B2 Compound having substituted anthracene ring structure and pyridoindole ring structure, and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2017-09-05 US disclosed
US-20150155496-A1 COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO LTD (JP) 2015-06-04 US disclosed
US-20150155496-A1 COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO LTD (JP) 2015-06-04 US disclosed
US-8927119-B2 Compound having substituted anthracene ring structure and pyridoindole ring structure, and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2015-01-06 US disclosed
US-8927119-B2 Compound having substituted anthracene ring structure and pyridoindole ring structure, and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2015-01-06 US disclosed
US-20120126220-A1 COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO., LTD. (JP) 2012-05-24 US disclosed
US-20120126220-A1 COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO., LTD. (JP) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150155496-A1 COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE SLCO2B1, PNPO, SLCO2A1 CYP11B1 793/4885CYP11B2 949/4885CYP17A1 652/4885
US-20120126220-A1 COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE SLCO2B1, PNPO, SLCO2A1 CYP11B1 793/4885CYP11B2 949/4885CYP17A1 652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.